Berkshire Biomedical Corporation is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA™), has been honored as a 2022 Top Texas Tech Startup in the new edition of StartupCity Magazine. The COPA is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of prescription medications only to a biometrically authenticated Intended User, with the goal of enhancing patient wellness by providing remote monitoring with advanced data analytics that are not dependent on patient self-reporting, allowing for improved adherence and informed medical decisions.
Top iTechnology Automation News: Zycus empowers the procurement & APIA community with the first-hand experience of AI magic through its transformative Merlin Experience Center
“Our inclusion as a Top Texas Tech Startup by StartupCity is a testament to the revolutionary cloud-based, physician-enabled COPA device and its potential to make a significantly positive impact on medication adherence, while addressing and helping to assure that a medication is delivered to the right person, in the right amount and at the right time,” stated John Timberlake, Chief Executive Officer of Berkshire. “One of the greatest challenges in treating chronic illnesses is that once a medication is dispensed to a patient, there is no ability to accurately know when the patient took the medicine, whether they took the correct dose, or whether the patient was the person who actually ingested that medicine. This creates significant challenges to healthcare providers who are making medical decisions for patients without the accurate knowledge of the patient’s medication adherence.”
Top iTechnology Cloud News:Tekion Launches Game-Changing AI-Powered CRM
Mr. Timberlake continued, “It is important to note that non-adherence is linked to hospital admissions, worse healthcare outcomes and higher healthcare costs. The initial intended use for COPA will include the delivery of opioids for the treatment of chronic pain and the delivery of methadone in Medication Assisted Therapy for the treatment of opioid use disorder. The Company plans to make its De No
Top iTechnology IOT News: Credo Expands High Performance Seagull Family With Integrated 50Gbps PAM4 VCSEL and EML Drivers
[To share your insights with us, please write to sghosh@martechseries.com]
